Antibiotic resistances are on the rise and as such, it behooves dermatologists to use antibiotics only when necessary and in combination with topical agents wherever possible in order to help stop this alarming trend.
Acute bacterial skin and skin structure infections are associated with unnecessary use of broad-spectrum antibiotics, leading to antibiotic resistance. Antimicrobial stewardship programs could be a very effective and useful approach to help stop the alarming trend of antibiotic resistance. Several strategies help optimize outcomes.
The drugs that physicians prescribe are generally believed to be safe, having typically undergone thorough FDA scrutiny. Nevertheless, adverse drug reactions do occur and knowing which drugs are common offenders and how to best identify potential offenders is crucial in optimally treating and managing patients with adverse drug reactions.
Erythematotelangiectatic rosacea, characterized by diffuse and persistent facial redness and telangiectasias, is a challenging disease to treat. Recent advances in laser and light therapies appear effective in improving these symptoms.
The development of novel targeted anticancer therapies are proving to have a significant impact in the treatment and management of cancer patients; however, these agents also are associated with a distinct set of cutaneous side effects. Learn more.
Dermatologists need to be vigilant and more aware of the type and frequency of skin cancers that can occur in patients with darker Fitzpatrick Skin Types, an expert says. In addition to examining the “typical” sites where these tumors occur, dermatologists should also carefully inspect the oral mucosa as well as the palms and soles.
Research has shown that dry eye syndrome is largely due to inflammation. Therefore, "soft" corticosteroids such as loteprednol etabonate ophthalmic suspension 0.5% (Lotemax, Bausch & Lomb) or fluorometholone ophthalmic suspension 0.1% (FML, Allergan), or cyclosporine ophthalmic emulsion 0.05% (Restasis, Allergan), may be effective.